Ambitious Franklin Avenue, Green Street project aims to improve O'Hare transportation
Construction will begin this spring on a large roadway improvement project along Franklin Avenue and Green Street in Franklin Park.
The project will expand the roadway, which stretches from Runge Street in Franklin Park to York Road in Bensenville, as part of a ongoing toll road I-490/IL-390 project to connect to O'Hare International Airport.
That project is slated to cost $534 million and is intended to improve access to the west side of O'Hare, thereby improving the immediate surrounding areas, according to Illinois Tollway.
The Franklin Avenue/Green Street portion will widen to allow the industrial corridor to accommodate more traffic, offer more pedestrian amenities and help truck access into a nearby railyard. The scope of the project should aid commuters and residents as well as commercial freight trucks driving from the airport to the train depot.
'[Companies] will be able to use interstates for more of their trucks,' said Nathan Roseberry, assistant superintendent of the Cook County Department of Transportation and Highways. 'We'll be going from a two-lane to a five-lane road on Franklin Street.'
With a new highway comes more demand on local surface routes. Due to the convergence of nearly all types of transportation hubs, updating the whole corridor is essential for shipping, officials said.
'The yard is directly adjacent to the airport, so you have air, rail and trucks all coexisting,' Roseberry said.
The project also will provide more traffic signals, bike and pedestrian lanes, landscape restoration, sewer repairs and curb upgrades for compliance with the Americans with Disabilities Act.
The project is expected to cost $34.5 million with the money coming from Cook County, Bensenville, Franklin Park, the tollway and the federal government. The project kicks off in coming weeks and will wrap up in 2027, though most of the construction will be finished in 2026, officials said.
Drivers can expect some traffic delays during the work and Roseberry said residents can check progress on the county's website.
'This one is a large enough project where we have a stand-alone page where we'll have updates,' he said. The website can be found by searching Green Street and Franklin Avenue Improvement Project.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
32 minutes ago
- Yahoo
O-I, GPI decry federal funding walkback for glass decarbonization projects
This story was originally published on Packaging Dive. To receive daily news and insights, subscribe to our free daily Packaging Dive newsletter. O-I Glass said Friday it is disappointed by the U.S. Department of Energy's announcement a week prior that it was terminating a more than $57 million award to the company. That money was supposed to go toward enhancements at the company's Zanesville, Ohio, glass manufacturing facility. 'The Zanesville project was designed to be a generational investment in American manufacturing, the state of Ohio, and to make our industry more competitive,' O-I Glass said in an emailed statement. 'With support from the DOE's Industrial Demonstrations Program, this pilot project aimed to integrate five proven, cutting-edge furnace technologies—waste heat recovery, gas/oxygen firing, batch and cullet pre-heating, and electric boost—into a single transformative system.' O-I said that this would have been 'the first time all five proven technologies were deployed together,' which the company said would have had energy reduction and economic benefits, and increased the use of recycled material. Specifically, the project could have added more than 300 contracting jobs and reduced emissions by 49%, also helping customers reach their scope 3 targets. O-I did not comment on the status of the project in the wake of the federal funding reversal. The company did, however, say in the statement it is 'evaluating all available options before the company due to this reversal.' 'O-I stands by the viability and potential impact of this project that was vetted and agreed upon by DOE's team of experts,' the company wrote. 'While the DOE's decision cites a shift in policy priorities and a reassessment of emissions accounting methodology, we believe the project remains aligned with the broader goals of strengthening domestic manufacturing, making American made products more competitive and sustainable.' O-I's project was one of 24 decarbonization awards on the chopping block in DOE's notice. Some others in the glass space were also affected, including Gallo Glass, which had planned to install a demonstration hybrid electric furnace at its Modesto, California, site, backed by a $75 million award. The list also extended far beyond glass; other companies affected included Exxon Mobil, Eastman, Kraft Heinz and Diageo. DOE said in its announcement that it 'found that these projects failed to advance the energy needs of the American people, were not economically viable and would not generate a positive return on investment of taxpayer dollars.' The Glass Packaging Institute railed against these cuts, what it called a 'surprising decision to abruptly terminate funding for multiple industrial decarbonization projects — including shovel-ready initiatives from U.S. glass manufacturers — while allowing projects from other material sectors, such as steel and aluminum to move forward.' 'Glass manufacturing recipients were informed that their projects did not 'effectuate current priorities' and lacked full-scope emissions modeling — despite providing shovel-ready, technologically sound, and financially responsible decarbonization strategies in support of the next generation of American manufacturing careers,' GPI said in an emailed statement. GPI said that other federal agencies have recognized the pressure domestic suppliers are under from Chinese competition. Such issues have previously prompted trade investigations by the U.S. Department of Commerce and International Trade Commission. 'Glass is an often overlooked American success story, and it's unacceptable to see vetted projects that advance American manufacturing competitiveness cut,' said GPI President Scott DeFife. 'The Department should lean into glass, not ignore it." GPI called on DOE to meet with industry stakeholders 'to ensure future opportunities reflect the full range of American manufacturing.' Recommended Reading DOE cancels $57M award for O-I Glass furnace project
Business Wire
4 hours ago
- Business Wire
Somnee Secures $10M to Revolutionize Sleep with New AI-Powered Neurotech Sleep Wearables
BERKELEY, Calif.--(BUSINESS WIRE)-- Somnee – the leader in sleep technology delivering pioneering AI-powered neurotech and software – today announced it has raised $10 million in a seed extension round. Somnee was launched in 2022 by renowned sleep expert, Dr. Matt Walker, PhD, and an esteemed group of scientists from the University of California, Berkeley. The round was led by Khosla Ventures, with participation from Marc Benioff's TIME Ventures, LEAD VC (founded by the Adidas family), the NBA's Orlando Magic ownership group (DeVos family), Seaside Ventures, Nelstone Ventures, and Metalab, among others. Unlocking health and wellness through better sleep Sleep is one of the most powerful levers for health, longevity, and performance. Despite spending one-third of our lives asleep, nearly one in three adults suffer from poor sleep, ranging from insufficient deep sleep to insomnia. Based on decades of sleep research and neuroscience, Somnee has developed an AI-powered headband that helps people fall asleep faster and maintain higher quality sleep for longer. Somnee uses proprietary electroencephalogram (EEG+) and AI technology to map each user's brain activity and deliver gentle, personalized stimulation that guides the brain into its natural sleep state. In a published sleep study, Somnee helped users fall asleep twice as fast, stay asleep over 30 minutes longer, and reduce tossing and turning by a third. It outperforms melatonin by four times, cognitive behavioral therapy for insomnia (CBT-i) by two times, and Ambien by one-and-a-half times. Its therapeutic modality is backed by clinical studies and covered by 24 patents. Introducing second-generation headband and AI operating system to scale company The new funds will support Somnee as it prepares to launch the second-generation of its award-winning smart sleep headband, featuring its proprietary SmartSleep AI operating system, which enables personalized brain mapping, real-time monitoring, and AI-powered interventions throughout the sleep cycle. The second-generation product is currently in a beta pilot with select NBA teams and their performance training staff. The company is scaling to address the $91.4 billion sleep aid market and advance its mission to improve sleep through personalized neuroscience. 'Enhanced sleep can radically improve happiness, energy, and purpose. As such, Somnee isn't just a health product: it's a tool for better leadership, deeper compassion, and smarter decisions,' said Marc Benioff, founder of TIME Ventures and Chair, Founder & CEO of Salesforce. 'It's been a critical element of my sleep hygiene since they launched, and I was a customer long before Tim reached out to invest in their pioneering tech.' The funding follows a milestone year for the company, including its selection for the NBA's 2025 Launchpad program, which supports the development of technologies that advance player health and performance, and winning best sleep technology awards and recognition from GQ Fitness Awards, Men's Journal, the Digital Health Hub Foundation Awards, and Fast Company's Next Big Things in Tech. 'Sleep is the cheapest, most underused longevity drug we have. Few factors impact health more critically. Whereas others attempt to track sleep, Somnee's uniquely non-invasive and drug-free approach tunes it every night with a headband as effortlessly as brushing your teeth. That's why we backed them from day zero,' said Vinod Khosla, founder of Khosla Ventures. Since joining 18 months ago, CEO Tim Rosa has led efforts to relocate manufacturing out of China and expand teams in Berkeley and India, enhance the company's next-generation hardware and proprietary SmartSleep AI operating system, and forged partnerships with Equinox Hotels and the NBA. Somnee is currently exploring additional partnerships with professional sports organizations, employers, and healthcare brands to build upon existing research linking sleep quality to athletic performance, employee productivity, and human longevity. 'We began building this technology to explore a provocative question: could a sleep aid communicate in the same electrical dialect as the brain itself? That is, an 'electroceutical,' not a pharmaceutical,' said Dr. Matt Walker. 'We're trying to speak to the brain in its own language – using gentle, precisely timed pulses of electricity, not unlike how a conductor uses subtle hand movements to guide an orchestra into harmony. The goal was to create what I call a 'blast radius' of benefit: deeper sleep, more efficient sleep, and a quicker descent into sleep itself by preparing the brain just before sleep, we're trying to drive more powerful deep-sleep brainwaves, and give you a faster entry into sleep to begin with.' About Somnee Somnee is on a mission to transform sleep and neurological health while fundamentally improving the human experience. The Somnee Smart Sleep headband combines clinically validated neuroscience and award-winning AI-powered neurotechnology to enhance the brain's optimal sleep signals naturally and has been proven to help people fall asleep faster, reduce nighttime awakenings, and improve overall deep sleep quality. Somnee was co-founded by world-leading neuroscientists, including Dr. Matthew Walker, Ph.D., author of New York Times bestseller Why We Sleep and Director of UC Berkeley's Center of Human Sleep Science; Dr. Robert Knight, M.D., Professor of Psychology and Neuroscience at UC Berkeley; and ex-Fitbit executive, Tim Rosa leads as CEO. The Somnee team has spent decades pioneering sleep research, brain health, wearables, and personalized non-invasive neurostimulation applications. Sleep is one of the most critical functions of the brain, and our deep understanding of the neuroscience of sleep uniquely positions us to help solve the sleep health epidemic.
Yahoo
9 hours ago
- Yahoo
Monte Rosa Therapeutics Announces FDA Clearance of IND Application for MRT-8102, a NEK7-Directed Molecular Glue Degrader for the Treatment of Multiple Inflammatory Diseases
MRT-8102, a highly selective NEK7-directed molecular glue degrader (MGD) developed to treat inflammatory conditions linked to NLRP3, IL-1β, and IL-6 dysregulation, expands Monte Rosa's clinical I&I portfolio Potency, selectivity, and long-lasting pharmacodynamics of MRT-8102 observed in preclinical studies create potential for clinical differentiation from competitive approaches for inflammatory diseases MRT-8102 Phase 1 clinical results, including data on safety, pharmacokinetics, NEK7 protein degradation, and key downstream pharmacodynamic markers, expected in H1 2026 BOSTON, June 10, 2025 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced U.S. Food and Drug Administration (FDA) clearance of an Investigational New Drug (IND) application for MRT-8102, a NEK7-directed MGD being developed for the treatment of inflammatory diseases driven by the NLRP3 inflammasome and IL-1β. The Company plans to initiate a Phase 1 study of MRT-8102 in the coming weeks and anticipates sharing initial results in H1 2026. 'The IND clearance of MRT-8102 is another important milestone in our quest to broadly establish MGDs as a modality in immunology and inflammatory (I&I) indications. MRT-8102, following on the heels of our VAV1-directed MGD MRT-6160, is our second IND specifically for I&I indications, and represents the only clinical-stage MGD that selectively targets NEK7, with potential to address multiple inflammatory diseases, including cardio-immunology, rheumatology, and respiratory indications,' said Markus Warmuth, M.D., Chief Executive Officer of Monte Rosa Therapeutics. 'We believe MRT-8102 could provide a highly differentiated clinical profile compared to IL-1 antibodies and NLRP3 inhibitors in development based on its potency, selectivity, and long-lasting pharmacodynamics. We look forward to initiating a Phase 1 healthy volunteer study in the coming weeks, with clinical results expected in H1 2026, including data on safety, pharmacokinetics, NEK7 protein degradation, and downstream pharmacodynamic markers. As part of the Phase 1 study, we plan to establish initial proof-of-concept (POC) for cardio-immunology indications by evaluating changes in C-reactive protein (CRP) and other key inflammatory markers in a cohort of subjects with high CRP levels.' Monte Rosa believes its preclinical studies support MRT-8102's potential to address multiple inflammatory diseases driven by the NLRP3 inflammasome, IL-1β and IL-6. MRT-8102 has demonstrated nanomolar-level degradation of NEK7 in vitro with no off-target activity observed, including related NEK family proteins. In non-human primates (NHPs), oral administration of MRT-8102 resulted in near-complete inhibition of downstream inflammatory markers in ex vivo stimulation assays, as well as improvements in pathological measures in inflammatory disease models. Furthermore, in a rabbit gout model, daily oral dosing of MRT-8102 was observed to reduce pathogenic effects, including a reduction in joint swelling and histopathology scores. Preclinical GLP toxicology studies suggest a considerable safety margin for MRT-8102, with a greater than 200-fold exposure margin over the projected human efficacious dose in both rats and NHPs. In addition to MRT-8102, Monte Rosa is also working to advance a second-generation NEK7 program with enhanced CNS penetration with an IND submission expected in 2026. Monte Rosa retains full worldwide rights to MRT-8102 and its second-generation CNS-optimized NEK7 MGDs. About MRT-8102MRT-8102 is a potent, highly selective, and orally bioavailable investigational molecular glue degrader (MGD) that targets NEK7 for the treatment of inflammatory diseases linked to NLRP3, IL-1β, and IL-6 dysregulation. NEK7 has been shown to be required for NLRP3 inflammasome assembly, activation and IL-1β release both in vitro and in vivo. Aberrant NLRP3 inflammasome activation and the subsequent release of active IL-1β and interleukin-18 (IL-18) has been implicated in multiple inflammatory disorders, including cardiovascular disease, gout, osteoarthritis, neurologic disorders including Parkinson's disease and Alzheimer's disease, and metabolic disorders. In a non-human primate model, MRT-8102 was shown to potently, selectively, and durably degrade NEK7, and resulted in near-complete reductions of IL-1β and caspase-1 following ex vivo stimulation of whole blood. MRT-8102 has demonstrated a considerable safety margin (>200-fold exposure margin over projected human efficacious dose) in GLP toxicology studies. About Monte RosaMonte Rosa Therapeutics is a clinical-stage biotechnology company developing highly selective molecular glue degrader (MGD) medicines for patients living with serious diseases in the areas of oncology, autoimmune and inflammatory diseases, and more. MGDs are small molecule protein degraders that have the potential to treat many diseases that other modalities, including other degraders, cannot. Monte Rosa's QuEEN™ (Quantitative and Engineered Elimination of Neosubstrates) discovery engine combines AI-guided chemistry, diverse chemical libraries, structural biology, and proteomics to rationally design MGDs with unprecedented selectivity. Monte Rosa has developed the industry's leading pipeline of MGDs, which spans autoimmune and inflammatory diseases, oncology, and beyond. Monte Rosa has a global license agreement with Novartis to advance VAV1-directed molecular glue degraders and a strategic collaboration with Roche to discover and develop MGDs against targets in cancer and neurological diseases previously considered impossible to drug. For more information, visit Forward-Looking Statements This communication includes express and implied 'forward-looking statements,' including forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements that are not historical facts and in some cases, can be identified by terms such as 'may,' 'might,' 'will,' 'could,' 'would,' 'should,' 'expect,' 'intend,' 'plan,' 'objective,' 'anticipate,' 'believe,' 'estimate,' 'predict,' 'potential,' 'continue,' 'ongoing,' or the negative of these terms, or other comparable terminology intended to identify statements about the future. Forward-looking statements contained herein include, but are not limited to, statements about our ability to grow our product pipeline, our ability to successfully complete research and further development and commercialization of our drug candidates in current or future indications, including the timing and results of our clinical trials and our ability to conduct and complete clinical trials, statements regarding our progress and speed of development of only-in-class and first-in-class molecular glue degrader therapeutics, statements around the Company's QuEEN™ discovery engine and the Company's view of its potential to rationally design MGDs with unprecedented selectivity, statements about the advancement and timeline of our preclinical and clinical programs, pipeline and the various products therein, including the ongoing development and progress of our NEK7-directed MGD, referred to as MRT-8102, our plans to initiate a Phase 1 study of MRT-8102 in the coming weeks and our expectations for the design and advancement of such Phase 1 study, including updates related to status, safety data, pharmacokinetics, NEK7 protein degradation, and key downstream pharmacodynamic markers and timing of data read-outs, including the planned readout in the first half of 2026, the Company's statements around the potential of MRT-8102 to address multiple inflammatory diseases driven by the NLRP3 inflammasome, IL-1β and IL-6, including cardio-immunology, rheumatology, and respiratory indications and the Company's belief that MRT-8102 could provide a highly differentiated clinical profile compared to IL-1 antibodies and NLRP3 inhibitors in development based on its potency, selectivity, and long-lasting pharmacodynamics, statements relating to MRT-8102's safety margin, as well as statements around the advancement and timeline of a second-generation NEK7 program and expectations to submit an IND to the FDA in 2026, the expected potential clinical benefit of any of our candidates, advancement and application of our platform, statements around our ability to capitalize on and potential benefits resulting from our research and translational insights, including announcements related to preclinical programs, statements regarding regulatory filings for our development programs, including the planned timing of such regulatory filings, such as IND applications, and potential review by regulatory authorities, as well as our expectations of success for our programs, among others. By their nature, these statements are subject to numerous risks and uncertainties, including those risks and uncertainties set forth in our most recent Annual Report on Form 10-K for the year ended December 31, 2024, filed with the U.S. Securities and Exchange Commission on March 20, 2025, and any subsequent filings, that could cause actual results, performance or achievement to differ materially and adversely from those anticipated or implied in the statements. You should not rely upon forward-looking statements as predictions of future events. Although our management believes that the expectations reflected in our statements are reasonable, we cannot guarantee that the future results, performance, or events and circumstances described in the forward-looking statements will be achieved or occur. Recipients are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date such statements are made and should not be construed as statements of fact. We undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, any future presentations, or otherwise, except as required by applicable law. Certain information contained in these materials and any statements made orally during any presentation of these materials that relate to the materials or are based on studies, publications, surveys and other data obtained from third-party sources and our own internal estimates and research. While we believe these third-party studies, publications, surveys and other data to be reliable as of the date of these materials, we have not independently verified, and make no representations as to the adequacy, fairness, accuracy or completeness of, any information obtained from third-party sources. In addition, no independent source has evaluated the reasonableness or accuracy of our internal estimates or research and no reliance should be made on any information or statements made in these materials relating to or based on such internal estimates and research. InvestorsAndrew Funderburkir@ MediaCory Tromblee, Scient PRmedia@
